Showing 112 of 112on this page. Filters & sort apply to loaded results; URL updates for sharing.112 of 112 on this page
Genmab to highlight expanding clinical profile of epcoritamab at ASH ...
Genmab announces Phase Ib/II trial outcomes of epcoritamab combo for DLBCL
Genmab Celebrates FDA Approval of Epcoritamab for Blood Cancer ...
New Data on Epcoritamab Presented by Genmab at ASH 2021
Genmab and Abbvie to ramp up Phase III studies of epcoritamab ...
Genmab Announces Topline Results for Epcoritamab in DLBCL ...
Epcoritamab From AbbVie, Genmab Shows Positive Topline Results in Phase ...
Genmab posts Phase 3 PFS gain for epcoritamab | GMAB Stock News
Genmab Reports Encouraging Regulatory Progress for Epcoritamab (EPKINLY ...
Genmab A/S (GMAB)’s Epcoritamab Delivers 95% Response in Lymphoma
Genmab to Present 20+ Epcoritamab Abstracts at ASH 2025 | GMAB Stock News
Genmab A/S (GMAB) Unveils Promising Rina-S and Epcoritamab Data at ASCO ...
Genmab preps US FDA filing for bispecific antibody epcoritamab in ...
Genmab Presents Pivotal Phase 3 Data for Epcoritamab at ASH 2025 ...
Genmab A/S: Genmab Announces Topline Results for Epcoritamab (DuoBody ...
Genmab and AbbVie’s epcoritamab fails in phase 3 lymphoma study ...
Genmab Announces Submissions of Regulatory Applications for Epcoritamab ...
Subcutaneous Epcoritamab Brings 82% Overall Response in Patients With R ...
Full article: Epcoritamab in B-cell malignancies: current status and ...
CD20 X CD3双特异抗体格局 近日， Genmab 和艾伯维宣布其靶向CD20xCD3的双特异抗体epcoritamab（GEN3013 ...
Epcoritamab and talquetamab near EMA approval in cancer
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with ...
PPT - Genmab/Abbvie's Epcoritamab Achieves a 100% Response Rate In ...
Another BiTE, epcoritamab by Genmab, is approved by FDA. BiTE is to ...
Genmab/Abbvie’s Epcoritamab achieves a 100% response rate in patients ...
Genmab Receives FDA Approval for EPKINLY Combo in FL | GMAB Stock News
Genmab's Epcoritamab Combination Drug Cuts Risk of Disease Progression ...
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial ...
Genmab Announces Data From Multiple Clinical Trials Showing Treatment ...
Genmab's Epcoritamab Achieves Stunning 96% Response Rate in Lymphoma ...
epcoritamab (GEN-3013) / Genmab, AbbVie
AbbVie and Genmab's Epcoritamab Phase 3 Trial: A Potential Game-Changer ...
Genmab’s epcoritamab combination meets key endpoints in phase 3 ...
Genmab's Epcoritamab Hits Key Goal in Advanced Lymphoma Study ...
Thuốc Epcoritamab điều trị u lympho tế bào B và u lympho nang
FDA Grants Breakthrough Therapy Designation to Epcoritamab for ...
Epcoritamab (Epkinly), a novel bispecific antibody to target cancer ...
Genmab Announces Positive Phase 3 EPCORE FL-1 Trial Results for ...
240 | EPCORITAMAB MONOTHERAPY DEMONSTRATES DEEP AND DURABLE RESPONSES ...
Genmab Stock: Recent Updates Support The Growth Narrative (NASDAQ:GMAB ...
Genmab (CPH:GMAB) Stock Price & Overview
Epcoritamab (TEPKINLY®) [Acthera]
ASH 2022: Subcutaneous Epcoritamab in Patients with Richter's Syndrome ...
AbbVie, Genmab’s Bispecific Antibody Epcoritamab Achieves High Rate of ...
Epcoritamab (GCT3013-02) – Blood Cancer Research WA
Epcoritamab Gets Label Expansion for Difficult-to-Treat R/R Follicular ...
记住所有FDA生物药 | 靶向CD20 x CD3双抗 | Epcoritamab | 弥漫性大B细胞淋巴瘤(DLBCL) - 知乎
BioCentury - Epcoritamab shows best-in-class potential for DLBCL
Lymphoma Australia Epcoritamab - New Treatment for DLBCL
Epcoritamab (GEN3013) | Anti-CD3/CD20 Antibody | MedChemExpress
Epcoritamab - Anwendung, Wirkung, Nebenwirkungen | Gelbe Liste
AbbVie to pay Genmab $750M upfront to form bispecific R&D pact ...
SUBCUTANEOUS EPCORITAMAB IN PATIENTS WITH RELAPSED/REFRACTORY B‐CELL ...
(PDF) Epcoritamab induces potent anti-tumor activity against malignant ...
FDA批准第2款CD3/CD20双抗：艾伯维/Genmab的Epcoritamab Armstrong 2023年5月19日，艾伯维 ...
Mechanism of Action - EPKINLY® (epcoritamab-bysp) HCP
Epcoritamab-bysp is approved by FDA for relapsed or refractory diffuse ...
10 Potential Blockbuster Drug Approvals in 2023 | Biopharma PEG
Epkinly (epcoritamab-bysp) / Genmab, AbbVie
DailyMed - EPKINLY- epcoritamab-bysp injection, solution
艾伯维和Genmab宣布Epcoritamab治疗复发性/难治性大B细胞淋巴瘤患者的1/2期研究关键结果_包括_Genmab_艾伯维
Genmab: Epkinly's Approval Not Big Enough Needle-Mover (Neutral ...
Epcoritamab有效率88%，双抗治疗肿瘤时代或将到来|剂量|细胞|其中|方面|淋巴瘤|-健康界
Genmab's EPCORE FL-1 Trial Success and FDA Priority Review Signal a ...
艾伯维重磅新型CD3/CD20双抗Epkinly（epcoritamab）获美FDA加速批准！-印塔健康官网
On June 26, 2024, the U.S. Food and Drug Administration (FDA) announced ...
Epcoritamab: A Game-Changer in B-Cell Malignancy Treatment and a Strong ...
RxTROSPECT — FDA Approve EPKINLY™ (epcoritamab-bysp) as the First ...
Genmab’s Epcoritamab: A Game-Changer in Outpatient Lymphoma Care and ...
Genmab's Epcoritamab: A Game-Changer in Lymphoma Treatment and a High ...
The U.S. Food and Drug Administration (FDA) Approves Epcoritamab-bysp ...
FDA批准第2款CD3/CD20双抗：艾伯维/Genmab的Epcoritamab医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
2024年6月26日FDA加速批准CD3/CD20双特异性抗体疗法Epcoritamab-bysp(艾可瑞妥单抗、Epkinly)用于治疗治疗 ...
AbbVie联手Genmab研发三种双抗，前者支付近40亿美元购买特许权 - 小桔灯网 - IIVD.NET
$康诺亚-B(02162)$ 创新药周报20230521：Epcoritamab获批，关注CD3×CD20双抗进展原创 ... - 雪球
FDA Approves Epcoritamab-bysp as the First Bispecific Antibody for ...
AbbVie and Genmab’s Real-World Study on Epcoritamab: A Potential Game ...
Epcoritamab-bysp Granted Accelerated Approval for Relapsed or ...
Epcoritamab: Revolutionizing Therapy for Diffuse Large B-cell Lymphoma
Epcoritamab: A Promising Treatment for B-NHL Shows Progress in AbbVie ...
FDA Approves Epcoritamab-bysp for Relapsed, Refractory Diffuse Large B ...
Epkinly (Epcoritamab-bysp): FDA Approved For Lymphoma
Genmab公布了艾可瑞妥单抗2 期 EPCORE® NHL-6 研究的最新结果
New data from the ongoing Phase 1/2 EPCORE™ NHL-1 clinical trial ...
FDA Approves Epcoritamab-bysp for Follicular Lymphoma Indications ...
RxTROSPECT — TEPKINLY® (epcoritamab) Receives Second European ...
Epkinly (Epcoritamab) how to use: Uses, Dosage, Side Effects ...
Epcoritamab-bysp Yields Long-Term Disease Remission in Patients with ...
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic ...
Epkinly (epcoritamab) dosing, indications, interactions, adverse ...
EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and ...
.png?format=1000w)
.png)
